Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

DiaSorin SpA stock

DIA.MI
IT0003492391
A0MTB2

Price

105.50
Today +/-
-0.05
Today %
-0.05 %

DiaSorin SpA stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the DiaSorin SpA stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the DiaSorin SpA stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the DiaSorin SpA stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze DiaSorin SpA's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

DiaSorin SpA Stock Price History

DateDiaSorin SpA Price
11/29/2024105.50 undefined
11/28/2024105.55 undefined
11/27/2024107.05 undefined
11/26/2024106.75 undefined
11/25/2024107.40 undefined
11/22/2024107.45 undefined
11/21/2024104.10 undefined
11/20/2024104.90 undefined
11/19/2024104.35 undefined
11/18/2024104.35 undefined
11/15/2024107.10 undefined
11/14/2024104.95 undefined
11/13/2024107.05 undefined
11/12/2024108.90 undefined
11/11/2024110.50 undefined
11/8/2024109.50 undefined
11/7/2024108.95 undefined
11/6/2024107.10 undefined
11/5/2024101.45 undefined
11/4/2024100.55 undefined
11/1/202499.66 undefined
10/31/2024100.00 undefined

DiaSorin SpA Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into DiaSorin SpA, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by DiaSorin SpA from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects DiaSorin SpA’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of DiaSorin SpA. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into DiaSorin SpA’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing DiaSorin SpA’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on DiaSorin SpA’s growth potential.

DiaSorin SpA Revenue, EBIT and net profit per share

DateDiaSorin SpA RevenueDiaSorin SpA EBITDiaSorin SpA Net Income
2029e1.87 B undefined595.28 M undefined0 undefined
2028e1.76 B undefined566.46 M undefined0 undefined
2027e1.55 B undefined446.43 M undefined346.52 M undefined
2026e1.41 B undefined364.92 M undefined252.46 M undefined
2025e1.3 B undefined317.77 M undefined219.33 M undefined
2024e1.2 B undefined275.25 M undefined191.38 M undefined
20231.15 B undefined237.85 M undefined159.85 M undefined
20221.36 B undefined375.32 M undefined240.91 M undefined
20211.24 B undefined441.4 M undefined310.97 M undefined
2020881.31 M undefined330.11 M undefined247.87 M undefined
2019706.32 M undefined222.46 M undefined175.74 M undefined
2018669.2 M undefined209.85 M undefined158.13 M undefined
2017637.49 M undefined197.56 M undefined139.88 M undefined
2016569.31 M undefined177.94 M undefined112.38 M undefined
2015499.18 M undefined156.07 M undefined100.42 M undefined
2014443.77 M undefined131.59 M undefined84.07 M undefined
2013434.8 M undefined132.4 M undefined83 M undefined
2012433.8 M undefined140.2 M undefined87.4 M undefined
2011440 M undefined163.5 M undefined99.6 M undefined
2010404.5 M undefined151.4 M undefined90.4 M undefined
2009304.1 M undefined105.2 M undefined70 M undefined
2008244.6 M undefined70.7 M undefined37.5 M undefined
2007202.3 M undefined46.1 M undefined25.2 M undefined
2006179.8 M undefined40.2 M undefined22.3 M undefined
2005156.5 M undefined27.3 M undefined10.4 M undefined

DiaSorin SpA Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
20052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0.160.180.20.240.30.40.440.430.430.440.50.570.640.670.710.881.241.361.151.21.31.411.551.761.87
-14.7412.8520.7924.5932.898.91-1.590.232.0712.6414.0311.955.025.5324.7940.4110.02-15.654.797.988.709.9213.346.54
57.6961.4563.3765.5770.0770.3071.1468.5968.8967.2768.3468.3767.6668.0169.1268.3366.6166.1364.5561.6057.0452.4847.7442.1339.54
90110128160213284313297299298341389431455488602824900741000000
1022253770909987838410011213915817524731024015919121925234600
-120.0013.6448.0089.1928.5710.00-12.12-4.601.2019.0512.0024.1113.6710.7641.1425.51-22.58-33.7520.1314.6615.0737.30--
-------------------------
-------------------------
505051.8555555.25554.354.454.454.8854.855555.5154.9255.0857.5955.9555.75000000
-------------------------
Details

Keystats

Revenue and Growth

The DiaSorin SpA Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the DiaSorin SpA is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
2005200620072008200920102011201220132014201520162017201820192020202120222023
                                     
6.18.78.416.847.962.764.1104.9105.1169.82270.36130.47173.3196.53202.14340.01403.02413.22403.39
43.844.752.262.775.9106.4116.6113.8117.4109.52105.61120.26128.82131.09132.51165.68217.59220.04198.56
00000000000000008.6632.2830.15
27.130.935.541.450.368.381.38486.4101.32106.19128.87142.8160.4171.13191.23298.05306.5315.5
5.13.43.84.65.45.66.810.58.710.2912.1715.7836.326.8524.981730.9756.9135.09
0.080.090.10.130.180.240.270.310.320.390.490.40.480.410.530.710.961.030.98
35.535.533.935.44257.662.765.366.372.2174.4992.1392.3394.98128.39140.5276.2268.45256.29
00.10.10.30.1000.20.50.510.220.030.030.030.030.0310.7432.1812.92
0000000000000000021.320
0.010.010.020.030.040.060.060.060.050.050.050.190.190.210.210.21.151.171.13
48.148.148.159.959.365.465.167.765.567.768.5163.2150.74162.62164.68154.77789.63826.35799.37
6.989.110.119.420.220.721.122.725.0820.9623.9927.7722.9934.135.2742.5583.4534.57
0.10.110.110.140.160.20.210.210.210.210.210.470.460.490.530.532.272.42.23
0.190.190.210.260.340.450.470.530.530.610.710.870.950.911.061.253.233.433.21
                                     
505055555555.755.755.955.955.9555.9555.9555.9555.9555.9555.9555.9555.9555.95
4.44.45.95.95.913.713.71618.218.1618.1618.1618.1618.1618.1618.1618.1618.1618.16
0.010.030.060.090.160.250.330.340.350.40.480.550.670.620.750.911.251.321.4
0000000038.856.375478.6722.92101.26103.4682.56166.23402.28364.31
0000000000000000000
0.070.090.120.150.220.320.40.410.460.530.610.70.760.790.931.061.491.81.84
20.222.927.728.829.840.538.437.236.639.3140.7847.6762.3357.2955.7365.4984.77104.2100.71
00000019.300000035.3341.1647.6765.3367.6866.16
1817.417.522.327.333.414.378.534.339.839.3757.754.8825.2420.7742.8543.2449.4143.6
0000000000000000000
16.79.95.15.38.88.88.68.16.83.012.326.5123.9120.64.814.21104.88120.02109.65
54.950.250.356.465.982.780.6123.877.782.1282.44131.88141.12138.45122.48160.21298.23341.31320.12
0.040.030.020.030.030.020.0100000.02000.020.031.291.231.08
0.70.5122.52.32.63.63.53.012.051.41.95.057.1410.07185.34229.31199.6
20.622.221.320.922.925.927.22530.936.7836.2648.0660.6557.6260.8589.484.985.7470.75
0.060.060.040.050.050.050.040.030.030.040.040.070.060.060.090.131.561.551.35
0.120.110.090.110.120.130.120.160.110.120.120.210.20.20.210.291.861.891.67
0.190.190.210.260.340.450.520.570.570.650.730.910.970.991.151.353.353.693.51
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of DiaSorin SpA provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand DiaSorin SpA's financial health and stability.

Assets

DiaSorin SpA's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that DiaSorin SpA must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of DiaSorin SpA after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into DiaSorin SpA's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200520062007200820092010201120122013201420152016201720182019202020212022
10222537709099878384100112139158175248310240
1314131417212629283032445350586195153
0000000000000000-122
-11,000-5,000-10,000-14,000-26,000-21,000-31,000-7,000-10,0000-2,000-6,000-37,0001,000-8,000-15,000-48,000-51,000
10311135130647141106114247
443321100000000000
1016152137556254444651515925423611891
233430496495108110107119138165167209232304400389
-14-17-16-19-27-28-28-32-32-30-32-37-42-52-55-74-117-113
-13-17-15-40-26-73-27-37-29-28-32-298-69-71-59-73-1,611-231
001-210-451-5210-261-27-18-31-1,493-118
000000000000000000
-0.02-0.01-0.020.010-0.01-0.01-0.01-0.01-000.05-0.03-0-0.03-0.011.32-0.12
006-5-6-2-66-222017-1219-657-26-8-159
-0.01-0.01-0.020-0.01-0.01-0.08-0.03-0.08-0.05-0.040.06-0.06-0.22-0.09-0.041.26-0.33
1-10-104-3-1-1-17-2257-13-9-204400
00000000-72-29-32-35-43-145-49-52-54-57
-3208311414003967-8128-868418263-161
9.416.213.829.936.767.479.777.775.689.13106.4128.17124.96157.09176.88229.74283.29275.66
000000000000000000

DiaSorin SpA stock margins

The DiaSorin SpA margin analysis displays the gross margin, EBIT margin, as well as the profit margin of DiaSorin SpA. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for DiaSorin SpA.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the DiaSorin SpA's sales revenue. A higher gross margin percentage indicates that the DiaSorin SpA retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the DiaSorin SpA's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the DiaSorin SpA's total revenue generated. When comparing the revenue margin year over year, investors can gauge the DiaSorin SpA's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the DiaSorin SpA. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the DiaSorin SpA's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

DiaSorin SpA Margin History

DiaSorin SpA Gross marginDiaSorin SpA Profit marginDiaSorin SpA EBIT marginDiaSorin SpA Profit margin
2029e64.55 %31.77 %0 %
2028e64.55 %32.2 %0 %
2027e64.55 %28.76 %22.33 %
2026e64.55 %25.84 %17.88 %
2025e64.55 %24.46 %16.88 %
2024e64.55 %22.88 %15.91 %
202364.55 %20.71 %13.92 %
202266.17 %27.57 %17.7 %
202166.64 %35.66 %25.13 %
202068.41 %37.46 %28.13 %
201969.19 %31.5 %24.88 %
201868.11 %31.36 %23.63 %
201767.75 %30.99 %21.94 %
201668.35 %31.26 %19.74 %
201568.49 %31.27 %20.12 %
201467.32 %29.65 %18.95 %
201368.93 %30.45 %19.09 %
201268.53 %32.32 %20.15 %
201171.34 %37.16 %22.64 %
201070.38 %37.43 %22.35 %
200970.24 %34.59 %23.02 %
200865.66 %28.9 %15.33 %
200763.32 %22.79 %12.46 %
200661.23 %22.36 %12.4 %
200557.96 %17.44 %6.65 %

DiaSorin SpA Stock Sales Revenue, EBIT, Earnings per Share

The DiaSorin SpA earnings per share therefore indicates how much revenue DiaSorin SpA has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue DiaSorin SpA earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates DiaSorin SpA's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of DiaSorin SpA’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating DiaSorin SpA's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

DiaSorin SpA Revenue, EBIT and net profit per share

DateDiaSorin SpA Sales per ShareDiaSorin SpA EBIT per shareDiaSorin SpA Earnings per Share
2029e35.15 undefined0 undefined0 undefined
2028e32.99 undefined0 undefined0 undefined
2027e29.11 undefined0 undefined6.5 undefined
2026e26.48 undefined0 undefined4.74 undefined
2025e24.36 undefined0 undefined4.11 undefined
2024e22.56 undefined0 undefined3.59 undefined
202320.6 undefined4.27 undefined2.87 undefined
202224.33 undefined6.71 undefined4.31 undefined
202121.49 undefined7.66 undefined5.4 undefined
202016 undefined5.99 undefined4.5 undefined
201912.86 undefined4.05 undefined3.2 undefined
201812.05 undefined3.78 undefined2.85 undefined
201711.59 undefined3.59 undefined2.54 undefined
201610.38 undefined3.24 undefined2.05 undefined
20159.1 undefined2.84 undefined1.83 undefined
20148.16 undefined2.42 undefined1.55 undefined
20137.99 undefined2.43 undefined1.53 undefined
20127.99 undefined2.58 undefined1.61 undefined
20118 undefined2.97 undefined1.81 undefined
20107.33 undefined2.74 undefined1.64 undefined
20095.53 undefined1.91 undefined1.27 undefined
20084.45 undefined1.29 undefined0.68 undefined
20073.91 undefined0.89 undefined0.49 undefined
20063.6 undefined0.8 undefined0.45 undefined
20053.13 undefined0.55 undefined0.21 undefined

DiaSorin SpA business model

DiaSorin SpA is an Italian medical technology company that specializes in the development and production of diagnostic solutions for serious diseases. The company was founded in 1968 in Saluggia, a small town in the Piedmont region of northern Italy. Since then, DiaSorin has experienced impressive growth and now operates worldwide. DiaSorin is a major player in the in-vitro diagnostics (IVD) market and offers a wide range of solutions for clinical laboratories and medical professionals. The company's business model is based on the development of innovative test systems that enable fast, reliable, and accurate diagnosis of diseases. The company's goal is to provide improved access to diagnostic opportunities for patients worldwide and support the entire medical practice. In its early days, DiaSorin mainly focused on the development and production of enzyme immunoassays (EIAs) and other immunochemical tests. However, over the years, the company has evolved and introduced a variety of product lines, including molecular diagnostic tests, automated immunoassay systems and instruments, and clinical laboratory software. Today, DiaSorin has four main business areas: Immunoassays, Molecular Biology, Automation, and Diagnosis Information Management. The Immunoassays business area, also known as diaMune, offers a wide range of immunoassay solutions based on various technologies, including chemiluminescence, ELISA, fluorescence, and multiplexing. The Molecular Biology business area, also known as DiaMolecular, develops and produces a broad spectrum of molecular diagnostic solutions, including tests for infectious diseases, oncological diseases, and genetic disorders. DiaMolecular's products provide fast, efficient, and highly accurate diagnosis of serious diseases, enabling early treatment and therapy. The third major business area, DiaSorin's automation solutions, offers instruments and automated testing systems that optimize laboratory processes, improve efficiency, and speed up test execution. These solutions not only increase the accuracy and reliability of diagnostic tests but also help reduce costs and workload in medical laboratories. Finally, DiaSorin's Diagnosis Information Management business area offers a variety of software solutions that assist medical professionals in managing and interpreting diagnostic data. These solutions enable faster and more accurate diagnosis and can also contribute to improving patient care and optimizing laboratory processes. DiaSorin is led by a strong and experienced management team committed to driving the company's growth through continuous innovation and expansion into new markets. With branches and subsidiaries around the world, DiaSorin is a key player in the global medical technology industry. Overall, DiaSorin is an innovative and forward-thinking company that continuously develops its technologies and solutions to improve the quality of life for millions of people worldwide. DiaSorin SpA is one of the most popular companies on Eulerpool.com.

DiaSorin SpA SWOT Analysis

Strengths

DiaSorin SpA has several strengths that contribute to its success in the market.

  • Strong brand reputation and recognition.
  • Extensive product portfolio offering a wide range of medical diagnostic solutions.
  • Technological expertise and innovative research and development capabilities.
  • Established distribution network and strong relationships with healthcare providers.
  • Global presence with operations in multiple countries.
  • Strong financial performance and stability.

Weaknesses

Despite its strengths, DiaSorin SpA also faces certain weaknesses that need to be addressed.

  • Dependence on key markets, making the company susceptible to economic fluctuations.
  • Reliance on a limited number of major suppliers for key components.
  • Challenges in effectively managing and integrating acquisitions.
  • Limited brand awareness in some regions.

Opportunities

DiaSorin SpA can leverage various opportunities to further expand its business and market position.

  • Increasing demand for medical diagnostics driven by the growing aging population.
  • Emerging markets offer potential for market penetration and growth.
  • Advancements in technology create opportunities for development of new products and solutions.
  • Potential collaborations and partnerships for research and development.
  • Expanding product offerings to address emerging healthcare needs.

Threats

DiaSorin SpA faces certain threats that could impact its performance and competitiveness.

  • Intense competition from existing and new players in the market.
  • Regulatory environment and compliance challenges.
  • Currency exchange rate fluctuations affecting international operations.
  • Technological advancements by competitors that may outpace DiaSorin's innovations.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

DiaSorin SpA Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

DiaSorin SpA historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

DiaSorin SpA shares outstanding

The number of shares was DiaSorin SpA in 2023 — This indicates how many shares 55.746 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue DiaSorin SpA earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates DiaSorin SpA's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of DiaSorin SpA’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating DiaSorin SpA's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

DiaSorin SpA dividend history and estimates

In 2023, DiaSorin SpA paid a dividend amounting to 1.1 EUR. Dividend means that DiaSorin SpA distributes a portion of its profits to its owners.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

Dividend Overview

The dividend per year chart for DiaSorin SpA provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify DiaSorin SpA’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating DiaSorin SpA's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

DiaSorin SpA Dividend History

DateDiaSorin SpA Dividend
2029e1.24 undefined
2028e1.24 undefined
2027e1.24 undefined
2026e1.24 undefined
2025e1.24 undefined
2024e1.24 undefined
20231.1 undefined
20221.05 undefined
20211 undefined
20200.95 undefined
20190.9 undefined
20182.65 undefined
20170.8 undefined
20160.65 undefined
20150.6 undefined
20140.55 undefined
20130.5 undefined
20121.29 undefined
20110.4 undefined
20100.2 undefined
20090.12 undefined
20080.1 undefined

DiaSorin SpA dividend payout ratio

In 2023, DiaSorin SpA had a payout ratio of 21.34%. The payout ratio indicates the percentage of the company's profits that DiaSorin SpA distributes as dividends.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

What is Yearly Payout Ratio?

The yearly payout ratio for DiaSorin SpA represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for DiaSorin SpA could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate DiaSorin SpA's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

DiaSorin SpA Payout Ratio History

DateDiaSorin SpA Payout ratio
2029e21.84 %
2028e21.97 %
2027e21.83 %
2026e21.71 %
2025e22.38 %
2024e21.41 %
202321.34 %
202224.39 %
202118.52 %
202021.11 %
201928.13 %
201893.03 %
201731.45 %
201631.72 %
201532.79 %
201435.59 %
201332.68 %
201280.12 %
201122.1 %
201012.2 %
20099.45 %
200814.71 %
200721.34 %
200621.34 %
200521.34 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for DiaSorin SpA.

DiaSorin SpA latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240.89 0.84  (-5.67 %)2024 Q3
6/30/20241.11 0.93  (-16.44 %)2024 Q2
3/31/20240.88 0.86  (-1.71 %)2024 Q1
12/31/20230.79 0.87  (10.43 %)2023 Q4
9/30/20230.98 0.46  (-53.05 %)2023 Q3
6/30/20230.91 0.84  (-7.59 %)2023 Q2
3/31/20230.75 0.77  (3.02 %)2023 Q1
9/30/20220.91 1.14  (25.41 %)2022 Q3
6/30/20221.11 1.04  (-6.39 %)2022 Q2
3/31/20221.15 1.47  (27.67 %)2022 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the DiaSorin SpA stock

Eulerpool World ESG Rating (EESG©)

58/ 100

🌱 Environment

44

👫 Social

69

🏛️ Governance

60

Environment

Scope 1 - Direct Emissions
4,627
Scope 2 - Indirect emissions from purchased energy
15,264
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
19,891
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees43.001
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

DiaSorin SpA shareholders

%
Name
Stocks
Change
Date
47.19689 % Finde SS25,163,45407/5/2024
8.77639 % Rosa (Carlo)4,679,21407/5/2024
4.40769 % Even Chen (Menachem)2,350,00007/5/2024
3.18118 % T. Rowe Price Associates, Inc.1,696,07307/5/2024
2.27134 % Capital Research Global Investors1,210,98819,0239/30/2024
1.66509 % Norges Bank Investment Management (NBIM)887,75853,0046/30/2024
1.62155 % Wellington Management Company, LLP864,542-80,1578/31/2024
1.52658 % Invesco Advisers, Inc.813,9094,4078/31/2024
1.27924 % The Vanguard Group, Inc.682,039-1,5169/30/2024
1.08212 % La Financi¿re de l'Echiquier576,9414888/31/2024
1
2
3
4
5
...
10

DiaSorin SpA Executives and Management Board

Mr. Carlo Rosa

(57)
DiaSorin SpA Chief Executive Officer, Executive Director, General Manager (since 1998)
Compensation 1.75 M

Dr. Chen Even

(60)
DiaSorin SpA Executive Director, Chief Commercial Officer (since 2007)
Compensation 857,254

Mr. Michele Denegri

(54)
DiaSorin SpA Non-Executive Chairman of the Board
Compensation 320,123

Mr. Giancarlo Boschetti

(83)
DiaSorin SpA Non-Executive Vice Chairman of the Board
Compensation 117,507

Ms. Roberta Somati

(54)
DiaSorin SpA Independent Director
Compensation 55,110
1
2
3
4

DiaSorin SpA Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SupplierCustomer0,600,970,810,940,900,55
SupplierCustomer0,420,950,760,870,760,14
SupplierCustomer-0,110,760,50-0,78-0,77-0,47
SupplierCustomer-0,16-0,330,160,460,24-0,18
SupplierCustomer-0,300,850,400,880,830,54
1

Most common questions regarding DiaSorin SpA

What values and corporate philosophy does DiaSorin SpA represent?

DiaSorin SpA, a leading biotechnology company, represents a set of core values and corporate philosophy that defines its operations. The company is driven by a commitment to innovation, aiming to develop and provide cutting-edge diagnostic solutions. DiaSorin SpA prioritizes quality, ensuring precise and reliable results in healthcare diagnostics to improve patient outcomes. With a strong emphasis on research and development, the company tirelessly works towards advancements in the field of diagnostics for a variety of diseases. DiaSorin SpA combines scientific expertise and technological advancements to deliver high-performance products that meet the evolving needs of the healthcare industry.

In which countries and regions is DiaSorin SpA primarily present?

DiaSorin SpA is primarily present in various countries and regions across the globe. Some of the main areas where the company operates include Italy, the United States, Europe, Asia Pacific, Latin America, and the Middle East. With its strong presence in multiple markets, DiaSorin SpA is able to cater to the healthcare and diagnostics needs of a wide range of customers worldwide.

What significant milestones has the company DiaSorin SpA achieved?

DiaSorin SpA has achieved several significant milestones in its corporate journey. The renowned Italian biotechnology company has excelled in multiple areas since its inception. DiaSorin has made notable progress in molecular diagnostics, infectious diseases, and hormonal testing. Over the years, the company has expanded its product portfolio, extended its global presence, and strengthened strategic partnerships. DiaSorin's innovative technologies and cutting-edge solutions have revolutionized the medical diagnostic industry. With a commitment to continuous innovation and exceptional customer service, DiaSorin SpA has established itself as a leading player in the international healthcare sector.

What is the history and background of the company DiaSorin SpA?

DiaSorin SpA is a leading global biotechnology company, specializing in the development and production of innovative diagnostic solutions. Founded in 1968 and headquartered in Italy, DiaSorin has grown to become a trusted name in the field of in vitro diagnostics. The company offers a wide range of high-quality products and services for clinical diagnostics, including immunoassays, molecular diagnostics, and automation systems. With a strong focus on research and development, DiaSorin continues to drive innovation in the healthcare industry. Today, it operates in more than 90 countries worldwide, serving healthcare professionals and patients with reliable and accurate diagnostic solutions.

Who are the main competitors of DiaSorin SpA in the market?

The main competitors of DiaSorin SpA in the market are Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers.

In which industries is DiaSorin SpA primarily active?

DiaSorin SpA is primarily active in the healthcare and diagnostics industry. As a leading company in this field, DiaSorin focuses on developing and manufacturing innovative solutions for clinical diagnostics and infectious diseases. With its extensive range of assays and instruments, DiaSorin serves various sectors including hospitals, laboratories, and research facilities. By combining technology and expertise, DiaSorin delivers reliable and accurate diagnostic solutions to support healthcare professionals in making informed medical decisions.

What is the business model of DiaSorin SpA?

DiaSorin SpA operates as a global leader in the field of biotechnologies. The company focuses on developing and manufacturing healthcare diagnostics solutions. DiaSorin's business model revolves around providing a wide range of innovative diagnostic tests to help physicians and laboratories in the accurate and timely diagnosis of diseases. By leveraging its advanced technology platforms, DiaSorin aims to improve patient care and outcomes by enabling early disease detection, monitoring treatment efficacy, and identifying potential risks. With a commitment to research and development, DiaSorin continually expands its product portfolio to address emerging healthcare needs and deliver reliable diagnostic solutions worldwide.

What is the P/E ratio of DiaSorin SpA 2024?

The DiaSorin SpA P/E ratio is 30.73.

What is the P/S ratio of DiaSorin SpA 2024?

The DiaSorin SpA P/S ratio is 4.89.

What is the Quality Investing of DiaSorin SpA?

The Quality Investing for DiaSorin SpA is 6/10.

What is the revenue of DiaSorin SpA 2024?

The expected DiaSorin SpA revenue is 1.2 B EUR.

How high is the profit of DiaSorin SpA 2024?

The expected DiaSorin SpA profit is 191.38 M EUR.

What is the business model of DiaSorin SpA

DiaSorin SpA is an internationally active company in the medical and diagnostics industry, providing customized solutions for analysis procedures and diagnostic tests. It is headquartered in Italy and has branches in Europe, North America, Asia, and Africa. DiaSorin is a leading provider of medical diagnostic tests worldwide, and it operates in three main business areas: diagnostics, infectious diseases, and lifestyle. The diagnostics segment includes products for the chemical analysis of blood, urine, and stool, as well as test kits for screening human hormones, vitamins, and tumor markers. The company also offers automated solutions for immunological tests. The infectious diseases segment specializes in tests for diseases such as HIV, Hepatitis B and C, and tuberculosis. DiaSorin provides tests for the diagnosis of infections caused by bacteria, viruses, and fungi. The lifestyle segment includes diagnostic tests for monitoring endocrine, metabolic, and autoimmune diseases, as well as tests for measuring Vitamin D levels. DiaSorin has established itself as a leader in the field of medical diagnostics and life sciences, developing innovative solutions to support healthcare professionals in diagnosis, treatment planning, and therapy monitoring. It has strong partnerships with clinical laboratories worldwide and collaborates closely with universities and research institutions to drive medical innovations and develop new tests. DiaSorin has also emerged as a leader in the development of diagnostic tests for COVID-19 and offers customized solutions to combat the pandemic. Overall, DiaSorin is a leading provider of diagnostic tests globally, offering a wide range of customized solutions and fostering innovation in medical diagnostics.

What is the DiaSorin SpA dividend?

DiaSorin SpA pays a dividend of 1.05 EUR distributed over payouts per year.

How often does DiaSorin SpA pay dividends?

The dividend cannot currently be calculated for DiaSorin SpA or the company does not pay out a dividend.

What is the DiaSorin SpA ISIN?

The ISIN of DiaSorin SpA is IT0003492391.

What is the DiaSorin SpA WKN?

The WKN of DiaSorin SpA is A0MTB2.

What is the DiaSorin SpA ticker?

The ticker of DiaSorin SpA is DIA.MI.

How much dividend does DiaSorin SpA pay?

Over the past 12 months, DiaSorin SpA paid a dividend of 1.1 EUR . This corresponds to a dividend yield of about 1.04 %. For the coming 12 months, DiaSorin SpA is expected to pay a dividend of 1.24 EUR.

What is the dividend yield of DiaSorin SpA?

The current dividend yield of DiaSorin SpA is 1.04 %.

When does DiaSorin SpA pay dividends?

DiaSorin SpA pays a quarterly dividend. This is distributed in the months of June, June, June, June.

How secure is the dividend of DiaSorin SpA?

DiaSorin SpA paid dividends every year for the past 0 years.

What is the dividend of DiaSorin SpA?

For the upcoming 12 months, dividends amounting to 1.24 EUR are expected. This corresponds to a dividend yield of 1.17 %.

In which sector is DiaSorin SpA located?

DiaSorin SpA is assigned to the 'Health' sector.

Wann musste ich die Aktien von DiaSorin SpA kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of DiaSorin SpA from 5/22/2024 amounting to 1.15 EUR, you needed to have the stock in your portfolio before the ex-date on 5/20/2024.

When did DiaSorin SpA pay the last dividend?

The last dividend was paid out on 5/22/2024.

What was the dividend of DiaSorin SpA in the year 2023?

In the year 2023, DiaSorin SpA distributed 1.05 EUR as dividends.

In which currency does DiaSorin SpA pay out the dividend?

The dividends of DiaSorin SpA are distributed in EUR.

All fundamentals about DiaSorin SpA

Our stock analysis for DiaSorin SpA Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DiaSorin SpA Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.